Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVI...
Gespeichert in:
| Veröffentlicht in: | Mycopathologia (1975) 2020-08, Vol.185 (4), p.599-606 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 606 |
|---|---|
| container_issue | 4 |
| container_start_page | 599 |
| container_title | Mycopathologia (1975) |
| container_volume | 185 |
| creator | Song, Ge Liang, Guanzhao Liu, Weida |
| description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Although there are few publications, COVID-19 patients, especially severely ill or immunocompromised, have a higher probability of suffering from invasive mycoses. Aspergillus and Candida infections in COVID-19 patients will require early detection by a comprehensive diagnostic intervention (histopathology, direct microscopic examination, culture, (1,3)-
β
-
d
-glucan, galactomannan, and PCR-based assays) to ensure effective treatments. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. We provide a clinical flow diagram to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients. |
| doi_str_mv | 10.1007/s11046-020-00462-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A633892625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633892625</galeid><sourcerecordid>A633892625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-bc7c6d8bc6b0a8965860642bde4eb8b38402c673b2974e10d9a6d7368cb368413</originalsourceid><addsrcrecordid>eNp9kktv1DAUhSMEokPhD7BAltjAwsWPxHZYVBqltIxUqRUvsbMcx5lxldhDnBT499x0SssghCIlke93zpWPTpY9p-SIEiLfJEpJLjBhBBP4Ybh8kC1oITkmirOH2YJwQnGuxNeD7ElKV4SAjMrH2QFnkkuZy0UWT6ewNh2qIvahdXb0MSS0TClab0bXoO9-3KCzLtYzdPFldYJpiS5NaFzv7Vu0RFXng7cwhTN04s06xDR6iy7dkLaz4bVD7RB7VG18ME-zR63pknt2-z3MPp---1S9x-cXZ6tqeY5tIYsR11Za0ajaipoYVYpCCSJyVjcud7WqucoJs0LympUyd5Q0pRGN5ELZGl455YfZ8c53O9W9a6wL42A6vR18b4afOhqv9yfBb_Q6XmvJy5zJAgxe3RoM8dvk0qh7n6zrOhNcnJJmOayWkLAC9OVf6FWchgDXA4orypSi5J6CuJ2GsCPstbOpXgrOVckEm9ce_YOC5ybvGFzr4XxP8HpPAMzofoxrM6WkVx8_7LNsx9ohpjS49i4PSvRcKb2rlIZK6ZtK6RJEL_5M8k7yu0MA8B2QYBTWbri__n9sfwEkEdOO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2438128810</pqid></control><display><type>article</type><title>Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Song, Ge ; Liang, Guanzhao ; Liu, Weida</creator><creatorcontrib>Song, Ge ; Liang, Guanzhao ; Liu, Weida</creatorcontrib><description>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Although there are few publications, COVID-19 patients, especially severely ill or immunocompromised, have a higher probability of suffering from invasive mycoses. Aspergillus and Candida infections in COVID-19 patients will require early detection by a comprehensive diagnostic intervention (histopathology, direct microscopic examination, culture, (1,3)-
β
-
d
-glucan, galactomannan, and PCR-based assays) to ensure effective treatments. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. We provide a clinical flow diagram to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.</description><identifier>ISSN: 0301-486X</identifier><identifier>EISSN: 1573-0832</identifier><identifier>DOI: 10.1007/s11046-020-00462-9</identifier><identifier>PMID: 32737747</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Antifungal agents ; Aspergillosis ; Biomedical and Life Sciences ; Candidiasis ; Candidiasis, Invasive - complications ; Candidiasis, Invasive - diagnosis ; Candidiasis, Invasive - therapy ; Caspofungin ; China ; Coronavirus Infections - complications ; Coronavirus Infections - diagnosis ; Coronaviruses ; COVID-19 ; Cryptococcosis ; Cryptococcosis - complications ; Cryptococcosis - diagnosis ; Cryptococcosis - therapy ; Editorial ; Eukaryotic Microbiology ; Fungal infections ; Health aspects ; Humans ; Infections ; Influenza ; Invasive Pulmonary Aspergillosis - complications ; Invasive Pulmonary Aspergillosis - diagnosis ; Invasive Pulmonary Aspergillosis - therapy ; Life Sciences ; Medical Microbiology ; Medical research ; Medicine, Experimental ; Methenamine ; Microbial Ecology ; Microbiology ; Molds (Fungi) ; Mucormycosis ; Mucormycosis - complications ; Mucormycosis - diagnosis ; Mucormycosis - therapy ; Mycoses ; Mycoses - complications ; Mycoses - diagnosis ; Mycoses - therapy ; Mycosis ; Pandemics ; Patients ; Plant Sciences ; Pneumonia, Viral - complications ; Pneumonia, Viral - diagnosis ; Risk factors ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Mycopathologia (1975), 2020-08, Vol.185 (4), p.599-606</ispartof><rights>Springer Nature B.V. 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Nature B.V. 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-bc7c6d8bc6b0a8965860642bde4eb8b38402c673b2974e10d9a6d7368cb368413</citedby><cites>FETCH-LOGICAL-c575t-bc7c6d8bc6b0a8965860642bde4eb8b38402c673b2974e10d9a6d7368cb368413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11046-020-00462-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11046-020-00462-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32737747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, Ge</creatorcontrib><creatorcontrib>Liang, Guanzhao</creatorcontrib><creatorcontrib>Liu, Weida</creatorcontrib><title>Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China</title><title>Mycopathologia (1975)</title><addtitle>Mycopathologia</addtitle><addtitle>Mycopathologia</addtitle><description>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Although there are few publications, COVID-19 patients, especially severely ill or immunocompromised, have a higher probability of suffering from invasive mycoses. Aspergillus and Candida infections in COVID-19 patients will require early detection by a comprehensive diagnostic intervention (histopathology, direct microscopic examination, culture, (1,3)-
β
-
d
-glucan, galactomannan, and PCR-based assays) to ensure effective treatments. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. We provide a clinical flow diagram to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.</description><subject>Antifungal agents</subject><subject>Aspergillosis</subject><subject>Biomedical and Life Sciences</subject><subject>Candidiasis</subject><subject>Candidiasis, Invasive - complications</subject><subject>Candidiasis, Invasive - diagnosis</subject><subject>Candidiasis, Invasive - therapy</subject><subject>Caspofungin</subject><subject>China</subject><subject>Coronavirus Infections - complications</subject><subject>Coronavirus Infections - diagnosis</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cryptococcosis</subject><subject>Cryptococcosis - complications</subject><subject>Cryptococcosis - diagnosis</subject><subject>Cryptococcosis - therapy</subject><subject>Editorial</subject><subject>Eukaryotic Microbiology</subject><subject>Fungal infections</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infections</subject><subject>Influenza</subject><subject>Invasive Pulmonary Aspergillosis - complications</subject><subject>Invasive Pulmonary Aspergillosis - diagnosis</subject><subject>Invasive Pulmonary Aspergillosis - therapy</subject><subject>Life Sciences</subject><subject>Medical Microbiology</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Methenamine</subject><subject>Microbial Ecology</subject><subject>Microbiology</subject><subject>Molds (Fungi)</subject><subject>Mucormycosis</subject><subject>Mucormycosis - complications</subject><subject>Mucormycosis - diagnosis</subject><subject>Mucormycosis - therapy</subject><subject>Mycoses</subject><subject>Mycoses - complications</subject><subject>Mycoses - diagnosis</subject><subject>Mycoses - therapy</subject><subject>Mycosis</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Plant Sciences</subject><subject>Pneumonia, Viral - complications</subject><subject>Pneumonia, Viral - diagnosis</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0301-486X</issn><issn>1573-0832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kktv1DAUhSMEokPhD7BAltjAwsWPxHZYVBqltIxUqRUvsbMcx5lxldhDnBT499x0SssghCIlke93zpWPTpY9p-SIEiLfJEpJLjBhBBP4Ybh8kC1oITkmirOH2YJwQnGuxNeD7ElKV4SAjMrH2QFnkkuZy0UWT6ewNh2qIvahdXb0MSS0TClab0bXoO9-3KCzLtYzdPFldYJpiS5NaFzv7Vu0RFXng7cwhTN04s06xDR6iy7dkLaz4bVD7RB7VG18ME-zR63pknt2-z3MPp---1S9x-cXZ6tqeY5tIYsR11Za0ajaipoYVYpCCSJyVjcud7WqucoJs0LympUyd5Q0pRGN5ELZGl455YfZ8c53O9W9a6wL42A6vR18b4afOhqv9yfBb_Q6XmvJy5zJAgxe3RoM8dvk0qh7n6zrOhNcnJJmOayWkLAC9OVf6FWchgDXA4orypSi5J6CuJ2GsCPstbOpXgrOVckEm9ce_YOC5ybvGFzr4XxP8HpPAMzofoxrM6WkVx8_7LNsx9ohpjS49i4PSvRcKb2rlIZK6ZtK6RJEL_5M8k7yu0MA8B2QYBTWbri__n9sfwEkEdOO</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Song, Ge</creator><creator>Liang, Guanzhao</creator><creator>Liu, Weida</creator><general>Springer Netherlands</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200801</creationdate><title>Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China</title><author>Song, Ge ; Liang, Guanzhao ; Liu, Weida</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-bc7c6d8bc6b0a8965860642bde4eb8b38402c673b2974e10d9a6d7368cb368413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antifungal agents</topic><topic>Aspergillosis</topic><topic>Biomedical and Life Sciences</topic><topic>Candidiasis</topic><topic>Candidiasis, Invasive - complications</topic><topic>Candidiasis, Invasive - diagnosis</topic><topic>Candidiasis, Invasive - therapy</topic><topic>Caspofungin</topic><topic>China</topic><topic>Coronavirus Infections - complications</topic><topic>Coronavirus Infections - diagnosis</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cryptococcosis</topic><topic>Cryptococcosis - complications</topic><topic>Cryptococcosis - diagnosis</topic><topic>Cryptococcosis - therapy</topic><topic>Editorial</topic><topic>Eukaryotic Microbiology</topic><topic>Fungal infections</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infections</topic><topic>Influenza</topic><topic>Invasive Pulmonary Aspergillosis - complications</topic><topic>Invasive Pulmonary Aspergillosis - diagnosis</topic><topic>Invasive Pulmonary Aspergillosis - therapy</topic><topic>Life Sciences</topic><topic>Medical Microbiology</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Methenamine</topic><topic>Microbial Ecology</topic><topic>Microbiology</topic><topic>Molds (Fungi)</topic><topic>Mucormycosis</topic><topic>Mucormycosis - complications</topic><topic>Mucormycosis - diagnosis</topic><topic>Mucormycosis - therapy</topic><topic>Mycoses</topic><topic>Mycoses - complications</topic><topic>Mycoses - diagnosis</topic><topic>Mycoses - therapy</topic><topic>Mycosis</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Plant Sciences</topic><topic>Pneumonia, Viral - complications</topic><topic>Pneumonia, Viral - diagnosis</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Ge</creatorcontrib><creatorcontrib>Liang, Guanzhao</creatorcontrib><creatorcontrib>Liu, Weida</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mycopathologia (1975)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Ge</au><au>Liang, Guanzhao</au><au>Liu, Weida</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China</atitle><jtitle>Mycopathologia (1975)</jtitle><stitle>Mycopathologia</stitle><addtitle>Mycopathologia</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>185</volume><issue>4</issue><spage>599</spage><epage>606</epage><pages>599-606</pages><issn>0301-486X</issn><eissn>1573-0832</eissn><abstract>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been sweeping across the globe. Based on a retrospective analysis of SARS and influenza data from China and worldwide, we surmise that the fungal co-infections associated with global COVID-19 might be missed or misdiagnosed. Although there are few publications, COVID-19 patients, especially severely ill or immunocompromised, have a higher probability of suffering from invasive mycoses. Aspergillus and Candida infections in COVID-19 patients will require early detection by a comprehensive diagnostic intervention (histopathology, direct microscopic examination, culture, (1,3)-
β
-
d
-glucan, galactomannan, and PCR-based assays) to ensure effective treatments. We suggest it is prudent to assess the risk factors, the types of invasive mycosis, the strengths and limitations of diagnostic methods, clinical settings, and the need for standard or individualized treatment in COVID-19 patients. We provide a clinical flow diagram to assist the clinicians and laboratory experts in the management of aspergillosis, candidiasis, mucormycosis, or cryptococcosis as co-morbidities in COVID-19 patients.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32737747</pmid><doi>10.1007/s11046-020-00462-9</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-486X |
| ispartof | Mycopathologia (1975), 2020-08, Vol.185 (4), p.599-606 |
| issn | 0301-486X 1573-0832 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A633892625 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antifungal agents Aspergillosis Biomedical and Life Sciences Candidiasis Candidiasis, Invasive - complications Candidiasis, Invasive - diagnosis Candidiasis, Invasive - therapy Caspofungin China Coronavirus Infections - complications Coronavirus Infections - diagnosis Coronaviruses COVID-19 Cryptococcosis Cryptococcosis - complications Cryptococcosis - diagnosis Cryptococcosis - therapy Editorial Eukaryotic Microbiology Fungal infections Health aspects Humans Infections Influenza Invasive Pulmonary Aspergillosis - complications Invasive Pulmonary Aspergillosis - diagnosis Invasive Pulmonary Aspergillosis - therapy Life Sciences Medical Microbiology Medical research Medicine, Experimental Methenamine Microbial Ecology Microbiology Molds (Fungi) Mucormycosis Mucormycosis - complications Mucormycosis - diagnosis Mucormycosis - therapy Mycoses Mycoses - complications Mycoses - diagnosis Mycoses - therapy Mycosis Pandemics Patients Plant Sciences Pneumonia, Viral - complications Pneumonia, Viral - diagnosis Risk factors Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 |
| title | Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T06%3A15%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fungal%20Co-infections%20Associated%20with%20Global%20COVID-19%20Pandemic:%20A%20Clinical%20and%20Diagnostic%20Perspective%20from%20China&rft.jtitle=Mycopathologia%20(1975)&rft.au=Song,%20Ge&rft.date=2020-08-01&rft.volume=185&rft.issue=4&rft.spage=599&rft.epage=606&rft.pages=599-606&rft.issn=0301-486X&rft.eissn=1573-0832&rft_id=info:doi/10.1007/s11046-020-00462-9&rft_dat=%3Cgale_pubme%3EA633892625%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2438128810&rft_id=info:pmid/32737747&rft_galeid=A633892625&rfr_iscdi=true |